Jump to content

FP-LAD

Add links
From Wikipedia, the free encyclopedia

FP-LAD
Clinical data
Other namesFluoro-PRO-LAD; F-PRO-LAD; Fluoropropyl-LAD; TRALA-16; 6-(3-Fluoropropyl)-6-nor-LSD; (8β)-N,N-Diethyl-6-(3-fluoropropyl)-9,10-didehydroergoline-8-carboxamide
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • (6aR,9R)-N,N-diethyl-7-(3-fluoropropyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC22H28FN3O
Molar mass369.484 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CCCF
  • InChI=1S/C22H28FN3O/c1-3-25(4-2)22(27)16-11-18-17-7-5-8-19-21(17)15(13-24-19)12-20(18)26(14-16)10-6-9-23/h5,7-8,11,13,16,20,24H,3-4,6,9-10,12,14H2,1-2H3/t16-,20-/m1/s1
  • Key:BFFBEQKSDONILF-OXQOHEQNSA-N

FP-LAD, also known as fluoro-PRO-LAD or as TRALA-16, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD; METH-LAD).[1] It is specifically a fluorinated derivative of PRO-LAD (6-propyl-6-nor-LSD) and an analogue of FLUORETH-LAD (FE-LAD; 6-ethyl-6-nor-LSD).[1]

The drug has been reported to act as a potent ligand of the serotonin 5-HT2 receptors.[1] It had affinities (Ki) of 0.93 nM at the serotonin 5-HT2A receptor, 1.8 nM at the serotonin 5-HT2B receptor, and 3.7 nM at the serotonin 5-HT2C receptor.[1] FP-LAD was assessed and found to be a full agonist of the serotonin 5-HT2A and 5-HT2C receptors, with EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy values of 0.48 nM (93%) and 1.7 nM (97%), respectively.[1] It had several-fold greater activational potency than LSD at the serotonin 5-HT2A and 5-HT2C receptors.[1]

The chemical synthesis of FP-LAD has been described.[1]

FP-LAD was patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed (Mind Medicine) in 2023.[1] It had also previously been described in an earlier patent by Andrew Kruegel in association with Gilgamesh Pharmaceuticals in 2022.[2] Hamilton Morris has described synthesizing FP-LAD and/or 1P-FP-LAD with Lizard Labs in 2025.[3][4]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h US 2023/0414583, Trachsel D, Liechti ME, Lustenberger F, "Lysergic acid derivatives with modified LSD-like action", published 28 December 2023, assigned to Mind Medicine Inc. 
  2. ^ WO 2022226408A1, Kruegel AC, "Novel ergolines and methods of treating mood disorders", published 25 April 2022, assigned to Gilgamesh Pharmaceuticals, Inc.  Example 13: Preparation of (6aR,9R)-N,N-diethyl-7-(cyclopropylmethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (13) [...]
  3. ^ Andrew Callaghan (27 September 2025). "The Fight for Legal Psychedelics (#12)". Channel 5 with Andrew Callaghan (Podcast). YouTube. Event occurs at 1:14:26–1:15:32. [...] I just made a really interesting variant of LSD. I don't know if I have to bleep this out, but it was propyl-fluoro-1-propionyl-nor-LSD. And 6-propylfluoro. [...]
  4. ^ Adam Jay Moskowitz (2 October 2025). "Drug Journalist Hamilton Morris on Why All Drugs Should Be Legal". A Cheese Course (Podcast). YouTube. Event occurs at 29:48–31:12. [...]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=FP-LAD&oldid=1318339170"